Type 2 Diabetes

Clinical Trial Finder

Many patients with type 2 diabetes are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Web-Delivered Interventions for Blood Sugar Control for Individuals With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Behavioral: Multicomponent online program;   Behavioral: Breath meter;   Behavioral: Text messages;   Behavioral: Diet-appropriate foods and cookbooks
Sponsor:   University of Michigan
Not yet recruiting - verified February 2016

Effect of Victoza on Dietary Preferences and Habit in Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Overweight
Interventions:   Drug: Liraglutide;   Other: Observation alone
Sponsor:   Centre Hospitalier Universitaire Dijon
Recruiting - verified February 2016

An Exploratory Study of DS-8500a on Beta Cell Function Using Hyperglycemic Clamp

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: DS-8500a;   Drug: placebo
Sponsor:   Daiichi Sankyo Co., Ltd.
Not yet recruiting - verified January 2016

The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP

Condition:   Type 2 Diabetes
Interventions:   Drug: GIP Bolus;   Drug: GIP Clamp;   Procedure: Oral glucose tolerance test (OGTT);   Procedure: hyperglycemic clamp
Sponsor:   Diabeteszentrum Bad Lauterberg im Harz
Completed - verified February 2016

The Curative Effect of the Length of the Jejunum Exclusion in Grstric Bypass Surgery for Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Procedure: short biliarypancreatic limb;   Procedure: long biliarypancreatic limb
Sponsor:   Weidong Tong
Recruiting - verified January 2016

Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy

Condition:   Type 2 Diabetes
Interventions:   Other: 1: incretin-based therapy;   Other: 2: other antidiabetic
Sponsors:   Assistance Publique - Hôpitaux de Paris;   Assistance Publique Hopitaux De Marseille;   Institut National de la Santé Et de la Recherche Médicale, France;   France: Centre National de la Recherche Scientifique;   Collège de France;   University of Paris 5 - Rene Descartes;   Pierre and Marie Curie University;   University Paris 7 - Denis Diderot;   Aix Marseille Université
Not yet recruiting - verified January 2016

Investigation Into the Effects of Blood Glucose Levels Upon Eating Behavior in Lean and Obese Non-diabetic and Diabetic Subjects

Condition:   Diabetes
Interventions:   Device: Continuous Glucose Monitoring System (CGMS);   Behavioral: Food log
Sponsors:   Yale University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2016

A Comparison Study of the Bioavailability of a Capsule Formulation of LGD-6972 to an Oral Solution Formulation

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: LGD-6972 Solution;   Drug: LGD-6972 Capsules
Sponsors:   Ligand Pharmaceuticals;   Medpace, Inc.
Not yet recruiting - verified January 2016

Vaccine Efficacy in Diabetic and Elderly Patients

Condition:   Inflammation
Intervention:   Biological: Influenza Virus Vaccine
Sponsors:   Tulane University School of Medicine;   Louisiana Clinical and Translational Science Center
Recruiting - verified February 2016

Interventional Study of Active Weight Management in Patients With Type 2 Diabetes and Obesity in Routine Clinical Practice During 12 Months.

Condition:   Type 2 Diabetes Mellitus (T2DM)
Intervention:   Behavioral: Lifestyle intervention
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified January 2016

Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Albiglutide Liquid Auto-injector;   Drug: Albiglutide Lyophilized DCC Pen Injector;   Drug: Placebo Liquid Auto-injector;   Drug: Placebo Lyophilized DCC Pen injector
Sponsor:   GlaxoSmithKline
Not yet recruiting - verified February 2016

Loop Duodenal Switch Surgery in Morbidly Obese Patients

Conditions:   Obesity;   Type-2 Diabetes Mellitus
Intervention:   Procedure: Loop duodenal switch
Sponsor:   Medical College of Wisconsin
Recruiting - verified January 2016

Salivary Transcriptome Biomarkers for Early Diabetes Detection

Conditions:   Pre-diabetes;   Type II Diabetes;   Insulin Resistance
Intervention:  
Sponsor:   PeriRx
Recruiting - verified December 2015

Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving Liraglutide

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: ITCA 650 20/60 mcg/day;   Drug: ITCA 650 60 mcg/day
Sponsor:   Intarcia Therapeutics
Recruiting - verified February 2016

Metabolic Effects of Angiotensin-(1-7)

Conditions:   Obesity;   Insulin Resistance;   Hypertension;   Metabolic Cardiovascular Syndrome
Interventions:   Drug: Angiotensin-(1-7);   Drug: Saline
Sponsor:   Vanderbilt University
Recruiting - verified February 2016

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 15 mg;   Drug: Placebo matching ertugliflozin;   Drug: Metformin;   Drug: Glimepiride
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Recruiting - verified February 2016

Hydroxychloroquine in Acute Coronary Syndrome: Prevention of Recurrent Cardiovascular Events

Conditions:   Myocardial Infarction;   Acute Coronary Syndrome;   Inflammation;   Hydroxychloroquine;   Antirheumatic Agents;   Cardiovascular Diseases;   Angina, Unstable
Interventions:   Drug: Hydroxychloroquine;   Drug: Placebo
Sponsors:   Helsinki University Central Hospital;   Finnish Foundation for Cardiovascular Research;   Orion Corporation, Orion Pharma
Not yet recruiting - verified February 2016

Metformin Plus Sorafenib for Advanced HCC

Condition:   Hepatocellular Carcinoma
Interventions:   Drug: Sorafenib;   Drug: Metformin
Sponsors:   Tianjin Medical University Cancer Institute and Hospital;   First Affiliated Hospital of Harbin Medical University;   Harbin Medical University;   Liaoning Tumor Hospital & Institute;   Shanghai Zhongshan Hospital;   Fudan University
Recruiting - verified December 2015

A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dulaglutide;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified January 2016

Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Empagliflozin;   Drug: Placebo;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

Long-term Safety and Efficacy of Empagliflozin as Add on to GLP-1 RA

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsor:   Boehringer Ingelheim
Recruiting - verified February 2016

Comparison of MyStar DoseCoach to Routine Titration in Adult Patients With Type 2 Diabetes Mellitus Using Toujeo

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine (U300);   Device: MyStar DoseCoach
Sponsor:   Sanofi
Recruiting - verified February 2016

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Conditions:   Diabetes;   Type 2 Diabetes Mellitus
Intervention:   Drug: biphasic insulin aspart 30
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2016

Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Placebo;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

Double-blind Sitagliptin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Ipragliflozin (MK-0431J-842)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Ipragliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

Hyperbaric Oxygen Therapy as Adjunctive Therapy to Scaling and Root-planing in the Management of Periodontitis in Patients With Type 2 Diabetes

Conditions:   Diabetes;   Periodontitis
Interventions:   Device: Hyperbaric Oxygen therapy;   Other: Conventional Wound Therapies
Sponsor:   Loma Linda University
Recruiting - verified January 2016

Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ipragliflozin;   Drug: Sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

A 12-week Study To Evaluate PF-06291874 Once a Day in Adults With T2DM Inadequately Controlled On Metformin

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: PF-06291874;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2016

Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)

Condition:   Type 2 Diabetes Mellitus
Intervention:   Drug: INSULIN GLARGINE
Sponsor:   Sanofi
Recruiting - verified February 2016

A Study to Assess the Safety and Efficacy of the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin (MK-0431-838)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Dapagliflozin;   Drug: Metformin;   Drug: Matching placebo to sitagliptin;   Drug: Matching placebo to dapagliflozin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Multicenter, Open-label, Long-term Study of SYR-472 (25 mg) in Patients With Type 2 Diabetes Mellitus Complicated by Severe Renal Impairment or End-stage Renal Failure

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SYR-472 25 mg;   Drug: Placebo + SYR-472 25 mg
Sponsor:   Takeda
Recruiting - verified January 2016

Phase II Safety and Efficacy Study of Oral ORMD-0801 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Type 2
Interventions:   Drug: ORMD-0801;   Drug: Placebo Comparator
Sponsors:   Oramed, Ltd.;   Integrium
Active, not recruiting - verified February 2016

A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)

Condition:   Type II Diabetes Mellitus
Interventions:   Drug: MK-8521;   Drug: Placebo;   Drug: Liraglutide;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

Specified Drug Use Results Survey of Ipragliflozin Treatment in type2 Diabetes Patients

Condition:   Type 2 Diabetes
Intervention:   Drug: Suglat
Sponsor:   Astellas Pharma Inc
Active, not recruiting - verified February 2016

Impact of a Virtual Diabetes Self-Care and Education Program on Diabetes-related Outcomes in Latinos With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Virtual Diabetes Self-Care and Education Program;   Device: Fitbit;   Device: Smartphone
Sponsors:   Joslin Diabetes Center;   Verizon Foundation;   Doctors Hospital at Renaissance
Recruiting - verified February 2016

Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus
Interventions:   Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
Sponsors:   GlaxoSmithKline;   Duke Clinical Research Institute
Recruiting - verified January 2016

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin 10 mg + linagliptin 5 mg;   Drug: empagliflozin 10 mg;   Drug: empagliflozin 25 mg + linagliptin 5 mg;   Drug: empagliflozin 25 mg;   Drug: Placebo
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Linagliptin;   Drug: Empagliflozin placebo + linagliptin placebo;   Drug: Empagliflozin + linagliptin low dose;   Drug: Linagliptin lacebo;   Drug: Empagliflozin + linagliptin high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo (ACHIEVE CONTROL REAL LIFE STUDY PROGRAM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: INSULIN GLARGINE (U300);   Drug: INSULIN GLARGINE (U100);   Drug: Insulin detemir (Levemir)
Sponsor:   Sanofi
Recruiting - verified February 2016

A Performance Evaluation of the Harmony 1 Sensors in Adults and Pediatrics

Conditions:   Type 1 Diabetes;   Type 2 Diabetes
Intervention:   Device: Harmony 1 Sensor
Sponsor:   Medtronic Diabetes
Not yet recruiting - verified January 2016

Anthocyanin-rich Blackcurrant and Vascular Function

Conditions:   Vascular Stiffness;   Inflammation
Interventions:   Other: Beverage: Spray dried blackcurrant powder dissolved in water;   Other: Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)
Sponsors:   University of Reading;   GlaxoSmithKline
Completed - verified February 2016

Nutritional Therapy and Education With Multimedia Application in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Nutritional therapy and education;   Behavioral: Nutritional therapy
Sponsors:   Coordinación de Investigación en Salud, Mexico;   National Council of Science and Technology, Mexico
Completed - verified May 2015

EndoBarrier® SANS™ in Over-weight or Obese Type 2 Diabetic Subjects

Conditions:   Obesity;   Type 2 Diabetes
Intervention:   Device: EndoBarrier SANS
Sponsors:   GI Dynamics;   University of Malaya
Terminated - verified February 2016

Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus.

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   AstraZeneca;   Antaros Medical AB;   Bioventure Hub;   43183 Mölndal;   Sweden
Recruiting - verified February 2016

FreeStyle Libre Pro Use in Primary & Secondary Care

Condition:   Diabetes Mellitus
Interventions:   Device: FreeStyle Libre Pro 4 sensor wears, 2 with reviews;   Device: FreeStyle Libre Pro 6 sensor wears, 4 with reviews;   Device: FreeStyle Libre Pro 3 sensor wears
Sponsor:   Abbott Diabetes Care
Active, not recruiting - verified February 2016

A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Without Control on Metformin Alone

Condition:   Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Dapagliflozin;   Drug: Glimepiride;   Other: Placebo
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Recruiting - verified January 2016

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Matching Placebo for Dapagliflozin
Sponsor:   AstraZeneca
Recruiting - verified February 2016

A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin degludec/liraglutide;   Drug: insulin glargine;   Drug: insulin aspart
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2016

Non-inteRvEntional Study to Observe rAtionaLe to Select add-on TherapY for Type 2 Diabetes Inadequately Controlled With Metformin

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified February 2016

A Phase 3, Randomized, Double-blind, Parallel-group, Comparative Study and a Phase 3, Open-label, Long-term Study of SYR-472 (100 mg) in Combination With Insulin in Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: SYR-472;   Drug: Placebo
Sponsor:   Takeda
Active, not recruiting - verified January 2016

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Insulin glargine U300 HOE901;   Drug: Insulin glargine HOE901
Sponsor:   Sanofi
Recruiting - verified February 2016

The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Dapagliflozin;   Drug: Placebo
Sponsors:   University of Padova;   Azienda Ospedaliera di Padova
Recruiting - verified January 2016

A Sleep and Media Intervention to Improve Adolescents' Metabolic Health and Weight Status

Condition:   Sleep
Interventions:   Behavioral: Sleep and Media Use Intervention;   Behavioral: Study Skills Control Group
Sponsor:   University of Alabama at Birmingham
Recruiting - verified December 2015

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Conditions:   Diabetes Mellitus, Type 2;   Non-alcoholic Fatty Liver Disease
Interventions:   Drug: Exenatide;   Drug: insulin glargine
Sponsors:   Fudan University;   Huadong Hospital;   Shanghai Minhang Central Hospital;   Shanghai 6th People's Hospital;   Shanghai Changzheng Hospital
Recruiting - verified November 2015

Saxagliptin in Combination With Dapagliflozin - Effects on Islet Cell Function

Condition:   Type2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin;   Drug: Placebo for Saxagliptin
Sponsor:   Prof. Dr. Thomas Forst
Recruiting - verified January 2016

A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD

Conditions:   Type 2 Diabetes;   Non-alcoholic Fatty Liver Disease
Intervention:   Drug: Oral administration of Lobeglitazone
Sponsor:   Yonsei University
Completed - verified January 2016

Effect of LIXIsenatide on the Renal System

Conditions:   Diabetic Kidney Disease;   Diabetic Nephropathy;   Diabetes Mellitus;   Glucagon-Like Peptide 1
Interventions:   Drug: Lixisenatide;   Drug: Insulin glulisine
Sponsor:   VU University Medical Center
Recruiting - verified February 2016

Investigating the Role of the Polyol Pathway in the Central Nervous System

Condition:   Hyperglycemia
Interventions:   Other: Brain MRS during hyperglycemic clamp;   Other: Analysis of Metabolites in cerebrospinal fluid
Sponsor:   Yale University
Recruiting - verified February 2016

A Phase 2 Dose-finding Study of TAK-272 in Patients With Type 2 Diabetes Mellitus and Microalbuminuria

Condition:   Type 2 Diabetes Mellitus and Microalbuminuria
Interventions:   Drug: TAK-272 tablets;   Drug: Placebo tablets;   Drug: Candesartan cilexetil tablets
Sponsor:   Takeda
Recruiting - verified January 2016

Insulin Sensitivity, Irisin and Adipokines as Outcome Parameters in Patients Undergoing Cardiac Surgery

Conditions:   Insulin Resistance;   Diabetes Mellitus Type 2;   Other Functional Disturbances Following Cardiac Surgery
Intervention:   Procedure: Cardiac surgery
Sponsors:   University Hospital, Basel, Switzerland;   McGill University
Recruiting - verified January 2016

The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects

Condition:   Insulin Sensitivity
Interventions:   Drug: Eritoran;   Other: D5W
Sponsor:   Nicolas Musi, MD
Recruiting - verified January 2016

Linagliptin as Add on to Basal Insulin in the Elderly

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

A Phase 1 Single/Multiple Dose Study Of PF-06293620 To Assess Safety, Tolerability And Pharmacokinetics In Subjects With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus
Interventions:   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo;   Biological: PF-06293620;   Biological: Placebo
Sponsor:   Pfizer
Recruiting - verified February 2016

Weight Loss-Independent Metabolic Effects of Roux-En-Y Gastric Bypass in Diabetes

Conditions:   Obesity;   Type 2 Diabetes
Interventions:   Procedure: Roux-en-Y gastric bypass surgery;   Behavioral: Low-calorie diet;   Procedure: BPD;   Procedure: SG;   Procedure: LAGB
Sponsors:   Washington University School of Medicine;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2016

A Study of Once-Daily RO6811135 in Participants With Type 2 Diabetes (T2D) Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Liraglutide;   Drug: Metformin;   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Forxiga Tablets Specific Clinical Experience Investigation for Long-term Use

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Physician Led Counseling in Management of Depression in Type 2 Diabetes Mellitus

Conditions:   Depression;   Type 2 Diabetes Mellitus
Interventions:   Behavioral: Physician Supported Care;   Other: Usual care
Sponsors:   Adwin Life Care;   NMP Medical Research Institute
Completed - verified January 2016

Hypertriglyceridaemia - Cause and Effects

Condition:   Hypertriglyceridaemia
Intervention:  
Sponsor:   Central Manchester University Hospitals NHS Foundation Trust
Recruiting - verified January 2016

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

Conditions:   Diabetes Mellitus, Type 2;   Hypertension
Interventions:   Drug: Empagliflizon low dose;   Drug: placebo;   Drug: Empagliflizon high dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Chiglitazar;   Drug: Sitagliptin
Sponsor:   Chipscreen Biosciences, Ltd.
Recruiting - verified January 2016

Effect of Neuromuscular Electrostimulation on Sympathetic Nerve Activity in Patients With Type 2 Diabetes (ELECTROSYMP2)

Conditions:   Type 2 Diabetes;   Insulin Resistance
Interventions:   Device: effect of neuromuscular electrostimulation (NMES);   Device: effect of neuro electrostimulation (NES);   Other: effect of voluntary contractions (VC)
Sponsor:   University Hospital, Caen
Not yet recruiting - verified January 2016

Safety and Efficacy of Saxagliptin for Glycemic Control in Non-Critically Ill Hospitalized Patient

Condition:   Diabetes Mellitus
Intervention:   Drug: Saxagliptin
Sponsor:   Brigham and Women's Hospital
Recruiting - verified February 2016

Paraoxonase and HDL Qualities in Glycaemia and Inflammation

Conditions:   Diabetes.;   Bariatric Surgery.
Intervention:  
Sponsors:   Central Manchester University Hospitals NHS Foundation Trust;   British Heart Foundation;   Juvenile Diabetes Research Foundation
Recruiting - verified January 2016

Pyridorin in Diabetic Nephropathy

Conditions:   Diabetic Nephropathy;   Diabetic Kidney Disease
Interventions:   Drug: Pyridorin;   Drug: Placebo
Sponsors:   NephroGenex, Inc.;   Collaborative Study Group (CSG);   Medpace, Inc.
Recruiting - verified February 2016

Fat Metabolism in OSA and COPD

Conditions:   Obstructive Sleep Apnea;   Chronic Obstructive Pulmonary Disease;   Obesity
Intervention:  
Sponsor:   Texas A&M University
Recruiting - verified February 2016

Effect of Electrostimulation on Glucose Profile of Patients With Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Physical Activity
Interventions:   Device: electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .;   Device: electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week
Sponsors:   University Hospital, Caen;   University Hospital, Rouen;   Amiens University Hospital;   University Hospital, Lille;   General Hospital Roubaix
Recruiting - verified January 2016

Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients

Condition:   Type 2 Diabetes
Interventions:   Drug: Chiglitazar;   Drug: Placebo
Sponsor:   Chipscreen Biosciences, Ltd.
Recruiting - verified January 2016

Pharmacokinetic Single Dose Trial of Empagliflozin in Children and Adolescents With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: empagliflozin medium dose;   Drug: empagliflozin high dose;   Drug: empagliflozin low dose
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

Evaluate the Efficacy and Safety of Saxagliptin Added to Insulin Monotherapy or to Insulin Combined With Metformin in Chinese Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Saxagliptin 5mg;   Drug: Placebo for Saxagliptin
Sponsor:   AstraZeneca
Active, not recruiting - verified January 2016

A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes

Condition:   Diabetes Mellitus Type 2
Interventions:   Biological: BMS-986036;   Biological: Placebo (Matching with BMS-986036)
Sponsor:   Bristol-Myers Squibb
Active, not recruiting - verified January 2016

Nutritional Intervention of Type II Diabetes Mellitus by Vitamin D in Qatar

Condition:   Insulin Resistance
Intervention:   Dietary Supplement: Vitamin D
Sponsor:   Supreme Council Of Health, Qatar
Recruiting - verified February 2016

Changing the Healthcare Delivery Model

Condition:   Diabetes Type 2
Interventions:   Behavioral: mobile health care application;   Behavioral: CHWs and mobile health care application;   Behavioral: Community Health Worker (CHW)
Sponsor:   George Washington University
Active, not recruiting - verified February 2016

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy
Interventions:   Drug: Canagliflozin;   Drug: Placebo
Sponsors:   Janssen Research & Development, LLC;   The George Institute for Global Health, Australia
Recruiting - verified February 2016

Impact of Physical Activity on Blood Glucose Stability and Energy Stores in Individuals With Type 1 Diabetes

Conditions:   Type 1 Diabetes Mellitus;   Exercise;   Hypoglycemia;   Carbohydrate Metabolism
Interventions:   Procedure: IHE first, CONT second;   Procedure: CONT first, IHE second;   Procedure: GLU first, GLU-FRU second;   Procedure: GLU-FRU first, GLU second
Sponsors:   University Hospital Inselspital, Berne;   University of Bern;   University of Lausanne
Enrolling by invitation - verified February 2016

Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus

Condition:   Diabetes Mellitus Type II
Interventions:   Drug: Liraglutide;   Drug: Insulin bolus;   Drug: GIK infusion
Sponsor:   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Recruiting - verified February 2016

Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound

Conditions:   Hepatitis C;   Hepatitis B;   Nonalcoholic Fatty Liver Disease (NAFLD);   Nonalcoholic Steatohepatitis (NASH)
Intervention:   Device: Transient elastography, acoustic radiation force impulse, magnetic resonance elastography
Sponsors:   Centre hospitalier de l'Université de Montréal (CHUM);   Canadian Institutes of Health Research (CIHR);   Centre de Recherche du Centre Hospitalier de l'Université de Montréal
Recruiting - verified January 2016

Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients

Condition:   Type 2 Diabetes Mellitus
Intervention:  
Sponsor:   Chang Gung Memorial Hospital
Completed - verified January 2016

Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Canagliflozin, 100 mg;   Drug: Canagliflozin, 300 mg;   Drug: Placebo
Sponsor:   Janssen Research & Development, LLC
Recruiting - verified January 2016

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Ertugliflozin 5 mg;   Drug: Ertugliflozin 10 mg;   Drug: Glimerpiride;   Drug: Placebo to Ertugliflozin;   Drug: Placebo to Glimepiride;   Drug: Metformin;   Drug: Sitagliptin
Sponsors:   Merck Sharp & Dohme Corp.;   Pfizer
Active, not recruiting - verified February 2016

Linagliptin Inpatient Trial

Condition:   Type 2 Diabetes
Interventions:   Drug: Linagliptin;   Drug: Basal Bolus;   Drug: Linagliptin;   Drug: Linagliptin + 50% Glargine dose on discharge;   Drug: Linagliptin + 80% Glargine
Sponsors:   Emory University;   Boston Medical Center;   Rush University;   University of Denver
Recruiting - verified February 2016

A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Ticagrelor 60 mg;   Drug: Ticagrelor placebo
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Metformin Combined With Gemcitabine as Adjuvant Therapy for Pancreatic Cancer After Curative Resection

Conditions:   Stage IA Pancreatic Adenocarcinoma;   Stage IB Pancreatic Adenocarcinoma;   Stage IIA Pancreatic Adenocarcinoma;   Stage IIB Pancreatic Adenocarcinoma
Interventions:   Drug: Gemcitabine;   Drug: Metformin;   Drug: placebo
Sponsor:   Xian-Jun Yu
Recruiting - verified February 2016

Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer

Conditions:   Breast Cancer;   Breast Tumors;   Cancer of Breast
Interventions:   Drug: Metformin;   Drug: Atorvastatin;   Procedure: Breast surgery
Sponsor:   Columbia University
Recruiting - verified February 2016

A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome

Condition:   Li-Fraumeni Syndrome
Intervention:   Drug: Metformin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified June 2015

Left Ventricular DYsfunction in DiAbetes

Conditions:   Diabetes Mellitus, Type 2;   Heart Diseases;   Left Ventricular Dysfunction
Intervention:  
Sponsor:   Heart Care Foundation
Completed - verified October 2013

Diet and Exercise Intervention in Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Behavioral: Optimum Lifestyle Intervention;   Behavioral: Standard Care
Sponsors:   Washington University School of Medicine;   National Dairy Council;   American Egg Board
Recruiting - verified February 2016

A Study of RO6811135 in Patients With Type 2 Diabetes Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Withdrawn - verified February 2016

Impact of Fluid Milk on Post-meal Glycemia and Insulinemia in Overwt/Obese Adults

Conditions:   Blood Glucose;   Blood Insulin
Interventions:   Other: Acute beverage (water) consumption;   Other: Acute beverage (Black Coffee) consumption;   Other: Acute beverage (Orange Juice) consumption;   Other: Acute beverage (Whole Milk) consumption;   Other: Acute beverage (2% Milk) consumption;   Other: Acute beverage (Skim Milk) consumption
Sponsors:   Purdue University;   Dairy Research Institute
Completed - verified February 2016

Specific Clinical Experience Investigation for Long-term Use of Bydureon

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified February 2016

PMS of Trazenta on the Long-term Use as Add-on Therapy

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified February 2016

A Study of Alegitazar in Patients With Type 2 Diabetes And Chronic Kidney Disease (Alerenal Study)

Condition:   Diabetes Mellitus, Type 2, Kidney Disease, Chronic
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Withdrawn - verified February 2016

A Study of Aleglitazar in Monotherapy in Patients With Type 2 Diabetes Mellitus Who Are Drug-Naïve to Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Diabetes Lifestyle Assessment and Educational Tools

Condition:   Type 2 Diabetes Mellitus
Interventions:   Procedure: I-ACE intervention;   Procedure: Standard Lifestyle Advice
Sponsors:   Ofra Kalter-Leibovici MD;   The Gertner Institute for Epidemiology & Health Policy Research;   Clalit Health Services;   European Foundation for the Study of Diabetes
Active, not recruiting - verified February 2016

Genetics of Insulin and Incretins in Cystic Fibrosis

Condition:   Cystic Fibrosis
Interventions:   Genetic: Blood or Saliva Sample Collection;   Other: Glucose -potentiated arginine (GPA) stimulation tests
Sponsors:   Children's Hospital of Philadelphia;   University of Pennsylvania
Recruiting - verified February 2016

Abnormal Post-partum Glucose Metabolism After Gestational Diabetes Diagnosed Before or After 24 Weeks of Gestation

Conditions:   Gestational Diabetes;   Type 2 Diabetes;   Glucose Intolerance
Intervention:   Biological: Post-partum oral glucose tolerance test
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Recruiting - verified February 2016

Specific Clinical Experience Investigation for Long-term Use of Exenatide (Byetta Subcutaneous Injection)

Condition:   Type 2 Diabetes
Intervention:  
Sponsor:   AstraZeneca
Recruiting - verified February 2016

Elucidation of Breast Milk Composition and Structure Over the First Year of Lactation: UC Davis Lactation Study

Conditions:   Healthy;   Gestational Diabetes Mellitus;   Type 2 Diabetes Mellitus
Intervention:  
Sponsors:   University of California, Davis;   California Dairy Research Foundation
Active, not recruiting - verified February 2016

A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes

Conditions:   Type 2 Diabetes;   Comparative Effectiveness of Glycemia-lowering Medications
Interventions:   Drug: Sulfonylurea (glimepiride);   Drug: DPP-4 inhibitor (sitagliptin);   Drug: GLP-1 receptor agonist (liraglutide);   Drug: Insulin (glargine)
Sponsors:   GRADE Study Group;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Heart, Lung, and Blood Institute (NHLBI);   Becton, Dickinson and Company;   Bristol-Myers Squibb;   Merck Sharp & Dohme Corp.;   Novo Nordisk A/S;   Hoffmann-La Roche;   Sanofi
Recruiting - verified February 2016

A Safety, Pharmacokinetics and Pharmacodynamics Study of RO6811135 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6811135
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of the Safety and Efficacy of MK-0431A XR in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-289)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin + Metformin XR FDC;   Drug: Placebo to Sitagliptin + Metformin XR;   Drug: Metformin XR;   Drug: Placebo to metformin XR;   Drug: Insulin glargine;   Biological: Background insulin
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

A Study of The Effect of Aleglitazar on Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Optical Frequency Domain Imaging (OFDI) and Vascular Healing After Stent Placement Diabetics Presenting With Acute Coronary Syndrome

Condition:   Coronary Artery Disease
Intervention:   Device: Resolute Integrity stent
Sponsor:   Emory University
Active, not recruiting - verified February 2016

Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease

Conditions:   Fatty Liver;   Dyslipidemias;   Diabetes Mellitus
Interventions:   Drug: atorvastatin;   Drug: Vitamin E
Sponsors:   Xin Gao;   Pfizer
Recruiting - verified February 2016

A Study on The Potential of Aleglitazar to Reduce Cardiovascular Risk in Patients With Stable Cardiovascular Disease and Glucose Abnormalities

Condition:   Cardiovascular Disease, Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of MK-3102 in Participants With Type 2 Diabetes Mellitus With Chronic Kidney Disease or Kidney Failure on Dialysis (MK-3102-019)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-3102;   Drug: Placebo to MK-3102;   Drug: Glipizide;   Drug: Placebo to glipizide;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified January 2016

Breast Milk and Infant Growth Among Lean, Overweight and Diabetic Mothers

Conditions:   Obesity;   Type 2 Diabetes;   Gestational Diabetes
Intervention:  
Sponsors:   University of Colorado, Denver;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Thrasher Research Fund
Recruiting - verified February 2016

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Aleglitazar in Combination With Metformin in Patients With Type 2 Diabetes Mellitus Who Are Inadequately Controlled With Sulfonylurea Alone or Sulfonylurea Plus Metformin Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study to Evaluate the Effect of Aleglitazar on Cardiac Energetics and Function in Patients With Type 2 Diabetes Mellitus and no History of Coronary Artery Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability

Conditions:   Type 2 Diabetes Mellitus;   Menopause;   Osteoporosis;   Osteopenia
Interventions:   Drug: Vildagliptin;   Drug: Gliclazide MR
Sponsor:   Centro de Diabetes Curitiba Ltda
Completed - verified February 2016

Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: OAD;   Drug: Trazenta
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Active, not recruiting - verified January 2016

Using Peer Mentors to Support PACT Team Efforts to Improve Diabetes Control

Condition:   Type 2 Diabetes Mellitus
Intervention:   Behavioral: Peer Mentoring
Sponsor:   VA Office of Research and Development
Recruiting - verified January 2016

The VALDIATE-D Study

Conditions:   Type 2 Diabetes;   Obesity
Interventions:   Drug: Calcitriol and Lisinopril;   Drug: Placebo
Sponsor:   Brigham and Women's Hospital
Completed - verified February 2016

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK-5823;   Other: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified February 2016

Vascular Impairment in Type II Diabetes Mellitus With Co-morbid Obstructive Sleep Apnea

Conditions:   Sleep Apnea, Obstructive;   Diabetes Mellitus
Interventions:   Device: Continuous positive airway pressure;   Device: Sham continuous positive airway pressure
Sponsors:   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center
Recruiting - verified February 2016

A Study in China Evaluating the Safety and Efficacy of Adding Sitagliptin to Stable Therapy With Sulfonylurea With or Without Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-253)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Placebo;   Drug: Gliclazide;   Drug: Glimepiride;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Safety and Efficacy Study of Exenatide Once Weekly in Adolescents With Type 2 Diabetes

Condition:   Children and Adolescent With Type 2 Diabetes
Interventions:   Drug: Exenatide Once Weekly;   Drug: Placebo
Sponsor:   AstraZeneca
Suspended - verified February 2016

Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes

Conditions:   Diabetes;   Diabetes Mellitus, Type 2
Interventions:   Drug: liraglutide;   Drug: placebo;   Drug: metformin
Sponsor:   Novo Nordisk A/S
Recruiting - verified February 2016

Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952;   Drug: RO6807952;   Drug: liraglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified February 2016

Study to Assess Safety & Efficacy of Sitagliptin as Initial Oral Therapy for Treatment of Type 2 Diabetes Mellitus in Pediatric Participants. (MK-0431-083)

Conditions:   Diabetes Mellitus;   Type 2 Diabetes
Interventions:   Drug: Sitagliptin;   Drug: Metformin;   Drug: Placebo to sitagliptin;   Drug: Placebo to metformin;   Drug: Glycemic Rescue 1;   Drug: Glycemic Rescue 2;   Biological: Glycemic Rescue 3
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

A Study of the Safety and Efficacy of MK-0431A in Pediatric Participants With Type 2 Diabetes Mellitus (MK-0431A-170)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Metformin;   Drug: Sitagliptin + Metformin FDC;   Drug: Placebo to Metformin;   Drug: Placebo to Sitagliptin + Metformin FDC;   Biological: Insulin;   Biological: Insulin glargine
Sponsor:   Merck Sharp & Dohme Corp.
Recruiting - verified February 2016

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo matching with Saxagliptin;   Drug: Metformin IR;   Drug: Metformin XR;   Drug: Saxagliptin;   Drug: Saxagliptin
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Active, not recruiting - verified February 2016

Mood and Insulin Resistance in Adolescents At-Risk for Diabetes

Conditions:   Depression;   Impaired Glucose Tolerance
Interventions:   Other: The Blues Program;   Other: Hey Durham
Sponsors:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institutes of Health Clinical Center (CC)
Completed - verified January 2016

A Pharmacodynamic/Pharmacokinetic Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus on Treatment With Lisinopril

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: lisinopril;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Glucagon-like Peptide 1 Agonist Exenatide for Improved Glucose Control and Cardiac Function in Patients With Aortocoronary Bypass

Conditions:   Coronary Artery Disease;   Decreased Left Ventricular Function
Intervention:   Drug: Exenatide
Sponsors:   Charles University, Czech Republic;   Eli Lilly and Company
Completed - verified January 2016

A Study of RO6807952 in Patients With Diabetes Mellitus Type 2

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO6807952
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Study to Compare Sitagliptin Versus Sulfonylurea Treatment During Ramadan Fasting in Patients With Type 2 Diabetes (MK-0431-262)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Sulfonylurea;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Home Exercise for Older Diabetics

Condition:   Diabetes Mellitus Type 2
Interventions:   Behavioral: home exercise/physical activity (PA) enhancement program with behavioral support;   Behavioral: flex and toning health education program
Sponsor:   VA Office of Research and Development
Active, not recruiting - verified February 2016

Cinnamon Bark, Water-Soluble Cinnamon Extract, and Metformin for Treatment of Type 2 DM.

Condition:   Diabetes
Interventions:   Drug: Group 1: Metformin;   Dietary Supplement: Group 2: Cinnamon Bark;   Dietary Supplement: Group 3: Cinnulin PF
Sponsor:   Mike O'Callaghan Federal Hospital
Recruiting - verified February 2016

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Placebo (Saxagliptin);   Drug: Metformin IR;   Drug: Placebo (Metformin);   Drug: Metformin (Active Rescue)
Sponsors:   Bristol-Myers Squibb;   AstraZeneca
Active, not recruiting - verified February 2016

Characterization of Metabolic Biomarkers in Varying Subjects

Conditions:   Obesity;   Type 2 Diabetes
Intervention:  
Sponsor:   CPL Associates
Recruiting - verified January 2016

Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Exenatide;   Drug: Placebo
Sponsors:   University Hospital, Caen;   Eli Lilly and Company
Recruiting - verified January 2016

Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)

Condition:   Type 2 Diabetes
Interventions:   Drug: MK-0941;   Drug: Comparator: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Molecular and Clinical Profile of Diabetes Mellitus and Its Complications

Conditions:   Diabetes Mellitus, Type 2;   Diabetic Nephropathy;   Obesity
Intervention:  
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified January 2016

A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours

Condition:   Diabetes
Intervention:   Device: Subcutaneous glucose monitoring device
Sponsors:   BioTex, Inc.;   Endocrinoloogy Associates Houston
Completed - verified February 2016

Januvia Re-examination Study (MK-0431-181)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Sitagliptin;   Drug: Sulfonylurea;   Biological: Insulin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study to Compare Taspoglutide and Insulin Glargine in Insulin-Naïve Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin and Sulfonylurea Combination Therapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Terminated - verified February 2016

A Study of Aleglitazar in Type 2 Diabetes Patients With Moderate Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: aleglitazar;   Drug: pioglitazone
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Aleglitazar;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Placebo;   Drug: RO5095932;   Drug: RO5095932
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Single Doses of RO4998452 in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of the Pharmacokinetics of Two Formulations of MK-1006 (MK-1006-010 AM1)(COMPLETED)

Condition:   Type 2 Diabetes
Interventions:   Drug: MK-1006 DFC;   Drug: MK-1006 FCT
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study of RO5095932 in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO5095932;   Drug: RO5095932;   Drug: metformin;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Effects of Pulsed Intravenous (IV) Insulin on Brittle and Uncontrolled Diabetes

Condition:   Diabetes Mellitus
Intervention:   Procedure: Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )
Sponsors:   Florida Atlantic University;   Advanced Diabetes Treatment Centers
Terminated - verified February 2016

A Study of RO4998452 in Type 2 Diabetes Patients With Varying Degrees of Renal Impairment

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: pioglitazone;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK8245 5 mg (twice a day) b.i.d.;   Drug: MK8245 50 mg b.i.d.;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified February 2016

The Effect of Sitagliptin in Type 2 Diabetes Mellitus With Inadequate Glycemic Control (MK0431-118)

Condition:   Diabetes Mellitus Non-insulin-dependent
Intervention:   Drug: sitagliptin
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified February 2016

A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of RO5093151 and RO5027838 in Patients With Type 2 Diabetes Mellitus on a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO5027838;   Drug: RO5027838;   Drug: RO5093151;   Drug: RO5093151
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide in Type 2 Diabetic Patients

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452;   Drug: RO4998452
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Multiple-Dose Study of MK-1006 (MK-1006-004)(TERMINATED)

Condition:   Type 2 Diabetes
Interventions:   Drug: MK-1006;   Drug: Comparator: Placebo comparator
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified February 2016

A Study to Test the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK1006 (MK-1006-002)(COMPLETED)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK1006;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study of the Safety, Tolerability and Effect on Glycemic Control of Taspoglutide Versus Insulin Glargine in Insulin Naive Type 2 Diabetic Patients Inadequately Controlled With Metformin Plus Sulphonylurea.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: insulin glargine;   Drug: metformin;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: metformin;   Drug: pioglitazone;   Drug: placebo;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: exenatide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Multiple Ascending Dose Study of RO4998452 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: RO4998452;   Drug: placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes

Condition:   Type 2 Diabetes
Interventions:   Drug: Placebo;   Drug: Exenatide;   Drug: Exenatide
Sponsors:   AstraZeneca;   inVentiv Health Clinical
Recruiting - verified January 2016

A Multiple Ascending Dose Study of R1511 in Patients With Type 2 Diabetes Mellitus.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RG1511
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of DPP-IV (3) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: RO4876904
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Comparative Study of Aleglitazar and Actos in Patients With Type 2 Diabetes Mellitus and Class II Heart Failure.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Titration Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Effect of EGCG on the Body's Response to Insulin

Conditions:   Hypertension;   Obesity;   Type 2 Diabetes;   Insulin Resistance
Intervention:   Drug: EGCG
Sponsor:   University of Maryland
Withdrawn - verified January 2016

A Study of a GLP-1 Analogue in Patients With Type 2 Diabetes Treated With Metformin.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide;   Drug: taspoglutide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)

Condition:   Diabetes Mellitus, Non-Insulin-Dependent
Interventions:   Drug: sitagliptin phosphate;   Drug: Comparator: voglibose
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study of Aleglitazar in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Actos;   Drug: Placebo;   Drug: aleglitazar
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Glyburide
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Drug-Drug Interaction Study of GK Activator (2) and Simvastatin in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Simvastatin
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sitagliptin phosphate;   Drug: Comparator: sitagliptin phosphate (MK0431);   Drug: Comparator: pioglitazone;   Drug: Comparator: placebo (unspecified)
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

MK-0431 Early Phase II Double-blind Study - Type 2 Diabetes Mellitus (0431-043)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks;   Drug: Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study of the Effect of Renal Impairment on the Activity of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Dose-Titration Study of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Intervention:   Drug: GK Activator (2)
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Sitagliptin Metformin/PPARg Agonist Combination Therapy Add-on (0431-052)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: sitagliptin;   Drug: Comparator: Placebo;   Drug: rosiglitazone;   Drug: metformin;   Drug: glipizide
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Condition:   Type 2 Diabetes Mellitus (T2DM)
Interventions:   Drug: sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day;   Drug: comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of GK Activator (2) in Patients With Type 2 Diabetes Mellitus Treated With a Stable Dose of Metformin

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: GK Activator (2);   Drug: Metformin
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

Enhancing Support for Women at Risk for Heart Disease

Conditions:   Cardiovascular Diseases;   Heart Diseases;   Coronary Disease;   Coronary Heart Disease Risk Reduction;   Diabetes Mellitus, Non-insulin Dependent
Interventions:   Behavioral: diet;   Behavioral: physical activity;   Behavioral: stress management;   Behavioral: smoking cessation
Sponsors:   Oregon Research Institute;   National Heart, Lung, and Blood Institute (NHLBI)
Completed - verified February 2016

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: DPP-IV Inhibitor;   Drug: Metformin;   Drug: Placebo
Sponsor:   Hoffmann-La Roche
Completed - verified February 2016

MK0431 (Sitagliptin) and Metformin Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-036)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily);   Drug: Comparator: MK0431 100 mg q.d. (q.d. = once daily);   Drug: Comparator: Placebo (Phase A)/Metformin (Phase B);   Drug: Comparator: Metformin 500 mg b.i.d.;   Drug: Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.;   Drug: Comparator: Metformin 1000 mg b.i.d.
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016

Pioglitazone Add-on Study in Patients With Type 2 Diabetes Mellitus

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Comparator: Sitagliptin;   Drug: Comparator: Placebo;   Drug: Comparator: Pioglitazone;   Drug: Metformin
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified February 2016